CIZZLE BIOTECHNOLOGY HOLDINGS ORD 0.01P overview

Hardman & Co Research Hardman & Co Research: Cizzle Biotechnology (CIZ): Considerable progress in first year since listing 11-Jul-2022 / 07:15 GMT/BST Hardman & Co Research on Cizzle Biotechnology (CIZ): Considerable progress in first year since listing Cizzle Biotechnology (Cizzle), focused on cancer diagnostics, was spun out of the University of York to exploit the biomarker, variant CIZ1b, for the early detection of different forms of lung cancer. While implementing this strategy over the...

Hardman & Co Research Hardman & Co Research: Cizzle Biotechnology (CIZ) Strategic alliance in China 08-Feb-2022 / 12:15 GMT/BST Hardman & Co Research: Strategic alliance in China Cizzle Biotechnology (Cizzle), focused on cancer diagnostics, was spun out of the University of York to exploit the biomarker, variant CIZ1b, for early detection of different forms of lung cancer. There is high medical need for a simple blood test, to be used alongside a positive chest scan, that allows early detection...

Hardman & Co Research Hardman & Co Research: Cizzle Biotechnology (CIZ): News flow driven by deals 07-Dec-2021 / 11:50 GMT/BST Hardman & Co Research: News flow driven by deals Cizzle Biotechnology (Cizzle), focused on cancer diagnostics, was spun out of the University of York to exploit the biomarker, variant CIZ1b, for early detection of different forms of lung cancer. There is high medical need for a simple blood test that allows early detection of lung cancer and potentially improve patient...

Hardman & Co Research Hardman & Co Research: Cizzle Biotechnology (CIZ): Keeping on-track 30-Sep-2021 / 08:00 GMT/BST Hardman & Co Research: Keeping on-track Cizzle Biotechnology (Cizzle), focused on cancer diagnostics, was spun out of the University of York to exploit the biomarker, variant CIZ1b, for early detection of different forms of lung cancer. There is high medical need for a simple blood test that allows early detection of lung cancer and potentially improve patient outcomes. Since...

Hardman & Co Research Hardman & Co Research: Cizzle Biotechnology (CIZ): Strategic collaboration with SGSC 20-Sep-2021 / 15:45 GMT/BST Hardman & Co Research: Strategic collaboration with SGSC Cizzle Biotechnology (Cizzle), focused on cancer diagnostics, was spun out of the University of York to exploit the biomarker, variant CIZ1b, for early detection of different forms of lung cancer. There is high medical need for a simple blood test, to be used alongside a positive chest scan, that allows...